Patent Grant11 Feb 2021 10:37
11 February 2021
N4 Pharma plc
("N4 Pharma" or the "Company")
Notification of Intention to Grant Patent
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that the University of Queensland ("UQ") has been notified by the European Patent Office ("EPO") of its intention to grant a European Patent in relation to Nuvec® specifically in respect of its composition, particulate materials and methods for making the particulate materials (the "Patent"). N4 Pharma has the exclusive worldwide rights to Nuvec® for therapeutic uses in humans and animals.
Having received the notification the next steps prior to formal grant will require UQ to confirm the particulars and translations with the EPO prior to publication of the grant after which the Patent will be validated on a country by country basis throughout Europe as determined by UQ and the Company. This process, resulting in the full grant of the Patent in each chosen territory, should take six to eight months.
Nigel Theobald, Chief Executive Officer of the Company, commented:
"The receipt of the intention to grant the primary Patent in respect of Nuvec® for Europe is a key milestone for the Company and should see other key jurisdictions where patents remain pending for Nuvec® follow suit.
"The timing is especially relevant as we undertake our most comprehensive in vivo studies to date starting with Nuvec® loaded with the Coronavirus plasmid currently underway and the shortly to commence study incorporating our various learnings from the optimisation work over the last eighteen months.
"It is also particularly important as discussions with potential collaborators continue. We look forward to providing a full update on all our work streams, including our oral and oncology work, when we publish our full year results for the year ended 31 December 2020 which is expected to be towards the end of February / early March."
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO
Via IFC Advisory
Luke Cairns, Executive Director